- Home
- RITR vs GOSS Comparison
RITR vs GOSS Comparison
Compare RITR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- GOSS
- Stock Information
- Founded
- RITR 2015
- GOSS 2015
- Country
- RITR Hong Kong
- GOSS United States
- Employees
- RITR N/A
- GOSS N/A
- Industry
- RITR
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- GOSS Health Care
- Exchange
- RITR NYSE
- GOSS Nasdaq
- Market Cap
- RITR 249.8M
- GOSS 212.9M
- IPO Year
- RITR 2024
- GOSS 2019
- Fundamental
- Price
- RITR $3.98
- GOSS $0.81
- Analyst Decision
- RITR
- GOSS Strong Buy
- Analyst Count
- RITR 0
- GOSS 5
- Target Price
- RITR N/A
- GOSS $9.20
- AVG Volume (30 Days)
- RITR 206.2K
- GOSS 2.3M
- Earning Date
- RITR 02-15-2025
- GOSS 11-07-2024
- Dividend Yield
- RITR N/A
- GOSS N/A
- EPS Growth
- RITR N/A
- GOSS N/A
- EPS
- RITR 0.04
- GOSS N/A
- Revenue
- RITR $32,198,033.00
- GOSS $105,322,000.00
- Revenue This Year
- RITR N/A
- GOSS N/A
- Revenue Next Year
- RITR N/A
- GOSS N/A
- P/E Ratio
- RITR $91.73
- GOSS N/A
- Revenue Growth
- RITR 74.80
- GOSS N/A
- 52 Week Low
- RITR $2.35
- GOSS $0.50
- 52 Week High
- RITR $8.75
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- GOSS 49.87
- Support Level
- RITR N/A
- GOSS $0.76
- Resistance Level
- RITR N/A
- GOSS $0.88
- Average True Range (ATR)
- RITR 0.00
- GOSS 0.08
- MACD
- RITR 0.00
- GOSS 0.01
- Stochastic Oscillator
- RITR 0.00
- GOSS 30.48
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.